Monoclonal antibodies and similar biological medicines have yet to translate into veterinary medicine fully.
Acting as a bridge between the most advanced capabilities in discovery, development, and manufacturing from the human pharma ecosystem, translating these capabilities into a world-leading bio-pharma platform for veterinary health.
Anterra incubated this company. Subsequent co-investors include F-Prime Capital, Google Ventures, Novo Holdings, Casdin Capital, Eight Roads, and Tekla Management.
Our other companies
Food marketplace helping people eat better effortlessly
Digital procurement platform for farm inputs and services
Innovative materials to extend fresh produce shelf life
Real-time data collection tools for farm machinery
Financial and data services for the fresh produce industry
Next-generation synthetic cellular controls
Drug discovery using machine learning
Genome engineering using CRSPR-Cas9
Novel flavor generation using modified brewer’s yeast
Plant-based enteral nutrition products